Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

Commercial performance of AAV gene therapies: Market review and future implications

  • Biopharma
Introduction In 2017, the FDA approved Luxturna for the treatment of L…

Read more